Valion Bio (VBIO) Cash from Financing Activities (2021 - 2025)
Valion Bio (VBIO) posted quarterly Cash from Financing Activities of $11.6 million for Q4 2025, up 887.35% year-over-year from $1.2 million in Q4 2024, and up 172.26% quarter-over-quarter from $4.3 million in Q3 2025.
Valion Bio (VBIO) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Valion Bio's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $11.6 million for Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 887.35% year-over-year to $11.6 million; the TTM figure through Dec 2025 stood at $18.3 million (up 323.52% YoY), while the FY2025 annual figure was $18.3 million, up 323.52% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $11.6 million, up from $4.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $14.9 million in Q4 2021, with the low at -$584000.0 in Q4 2022.
- The 5-year median for Cash from Financing Activities is $1.4 million (2021), against an average of $3.0 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities slumped 103.92% in 2022, then soared 7627.27% in 2024.
- Valion Bio's Cash from Financing Activities stood at $14.9 million in 2021, then plunged by 103.92% to -$584000.0 in 2022, then soared by 850.17% to $4.4 million in 2023, then slumped by 73.11% to $1.2 million in 2024, then soared by 887.35% to $11.6 million in 2025.
- Business Quant data shows VBIO's Cash from Financing Activities at $11.6 million in Q4 2025, $4.3 million in Q3 2025, and $2.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.63 Mn |
| Dec 31, 2025 | 11.63 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 2.36 Mn |
| Jun 30, 2025 | 2.36 Mn |
| Mar 31, 2025 | 82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | 1.18 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | -97,000.00 |
| Sep 30, 2024 | -97,000.00 |
| Jun 30, 2024 | 3.31 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | -61,000.00 |
| Mar 31, 2024 | -61,000.00 |
| Sep 30, 2023 | 4.38 Mn |
| Sep 30, 2023 | 4.38 Mn |
| Jun 30, 2023 | -44,000.00 |
| Jun 30, 2023 | -44,000.00 |